SG11201703426PA - Anti-pdgf-b antibodies and methods of use - Google Patents

Anti-pdgf-b antibodies and methods of use

Info

Publication number
SG11201703426PA
SG11201703426PA SG11201703426PA SG11201703426PA SG11201703426PA SG 11201703426P A SG11201703426P A SG 11201703426PA SG 11201703426P A SG11201703426P A SG 11201703426PA SG 11201703426P A SG11201703426P A SG 11201703426PA SG 11201703426P A SG11201703426P A SG 11201703426PA
Authority
SG
Singapore
Prior art keywords
pdgf
antibodies
methods
Prior art date
Application number
SG11201703426PA
Other languages
English (en)
Inventor
Marc Bedoucha
Sebastian Breuer
Stefan Dengl
Christian Gassner
Guy Georges
Sabine Gruener
Guido Hartmann
Peter Michael Huelsmann
Joerg Moelleken
Olaf Mundigl
Joerg Thomas Regula
Barbara Weiser
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201703426PA publication Critical patent/SG11201703426PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201703426PA 2014-11-10 2015-11-06 Anti-pdgf-b antibodies and methods of use SG11201703426PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192519 2014-11-10
PCT/EP2015/075877 WO2016075036A1 (en) 2014-11-10 2015-11-06 Anti-pdgf-b antibodies and methods of use

Publications (1)

Publication Number Publication Date
SG11201703426PA true SG11201703426PA (en) 2017-05-30

Family

ID=51947140

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703426PA SG11201703426PA (en) 2014-11-10 2015-11-06 Anti-pdgf-b antibodies and methods of use

Country Status (15)

Country Link
US (1) US10087246B2 (enExample)
EP (1) EP3218400A1 (enExample)
JP (1) JP6946184B2 (enExample)
KR (1) KR20170082520A (enExample)
CN (1) CN107148429B (enExample)
AR (1) AR102593A1 (enExample)
AU (1) AU2015345322A1 (enExample)
BR (1) BR112017009792A2 (enExample)
CA (1) CA2963723A1 (enExample)
IL (1) IL251286A0 (enExample)
MX (1) MX2017005975A (enExample)
RU (1) RU2017120361A (enExample)
SG (1) SG11201703426PA (enExample)
TW (1) TW201630934A (enExample)
WO (1) WO2016075036A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256340A1 (en) 2009-04-07 2010-10-07 Ulrich Brinkmann Trivalent, bispecific antibodies
EP3218402A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-il-1beta antibodies and methods of use
SG11201703428SA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Bispecific antibodies and methods of use in ophthalmology
CN107001456A (zh) 2014-11-10 2017-08-01 豪夫迈·罗氏有限公司 抗ang2 抗体及使用方法
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
CN107849126B (zh) * 2015-07-29 2022-04-08 阿勒根公司 仅有重链的抗ang-2抗体
WO2020219774A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anthracycline antibody-drug conjugates and uses thereof
EP4126940A1 (en) 2020-03-30 2023-02-08 F. Hoffmann-La Roche AG Antibody that binds to vegf and pdgf-b and methods of use
JP2024505195A (ja) * 2021-01-25 2024-02-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法
TW202540203A (zh) * 2024-01-08 2025-10-16 日商中外製藥股份有限公司 結合pdgf-b與pdgf-d的抗原結合分子及使用方法
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
ES2567198T3 (es) 2003-01-24 2016-04-20 Applied Molecular Evolution, Inc. Antagonistas de la IL-1 beta humana
KR101471732B1 (ko) * 2003-08-27 2014-12-16 옵쏘테크 코포레이션 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
DE102004062361A1 (de) * 2004-12-10 2006-06-22 Cocreate Software Gmbh & Co. Kg Verfahren zur Ableitung von technischen Zeichungen aus 3D Modellen mit mindestens zwei kollidierenden 3D Körpern
BRPI0519596B1 (pt) * 2004-12-21 2022-01-18 Astrazeneca Ab Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
AU2013283296A1 (en) 2012-06-28 2015-02-05 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
NZ702201A (en) * 2012-07-13 2018-01-26 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
CA2890471C (en) * 2012-11-08 2021-07-27 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
AU2013343099A1 (en) * 2012-11-09 2015-05-14 Pfizer Inc. Platelet-derived growth factor B specific antibodies and compositions and uses thereof
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
EP3218402A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-il-1beta antibodies and methods of use
CN107001456A (zh) 2014-11-10 2017-08-01 豪夫迈·罗氏有限公司 抗ang2 抗体及使用方法
SG11201703428SA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Bispecific antibodies and methods of use in ophthalmology

Also Published As

Publication number Publication date
KR20170082520A (ko) 2017-07-14
AR102593A1 (es) 2017-03-08
TW201630934A (zh) 2016-09-01
JP2017534645A (ja) 2017-11-24
US20170247440A1 (en) 2017-08-31
US10087246B2 (en) 2018-10-02
CN107148429A (zh) 2017-09-08
WO2016075036A1 (en) 2016-05-19
BR112017009792A2 (pt) 2018-02-27
JP6946184B2 (ja) 2021-10-06
CA2963723A1 (en) 2016-05-19
RU2017120361A (ru) 2018-12-13
RU2017120361A3 (enExample) 2019-05-29
CN107148429B (zh) 2021-12-03
IL251286A0 (en) 2017-05-29
MX2017005975A (es) 2017-06-29
AU2015345322A1 (en) 2017-04-06
EP3218400A1 (en) 2017-09-20

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
IL279606A (en) Anti-TREM2 antibodies and methods of using them
IL257636A (en) Anti-tigit antibodies and methods of use
IL251868A0 (en) Anti-tim3 antibodies and methods of use
ZA201703167B (en) Anti-cd79b antibodies and methods of use
ZA201800315B (en) Anti-jagged1 antibodies and methods of use
IL248399A0 (en) New anti-43rnf antibodies and methods of use
IL247754A0 (en) Antibodies against mcam and related methods of use
ZA201701674B (en) Novel anti-mfi2 antibodies and methods of use
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use